Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Neurofeedback to Treat Chemotherapy Induced Peripheral Neuropathy

NCT04560673 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04560673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Neurofeedback to Treat Chemotherapy Induced Peripheral Neuropathy
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 10, 2020
Completion date
December 31, 2026
Enrollment
336 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced peripheral neuropathy, hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm